3.03
price down icon7.06%   -0.23
pre-market  Vorhandelsmarkt:  3.07   0.04   +1.32%
loading
Schlusskurs vom Vortag:
$3.26
Offen:
$3.23
24-Stunden-Volumen:
420.90K
Relative Volume:
0.24
Marktkapitalisierung:
$325.48M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-2.7054
EPS:
-1.12
Netto-Cashflow:
$-120.82M
1W Leistung:
+1.68%
1M Leistung:
-12.68%
6M Leistung:
-65.25%
1J Leistung:
-76.18%
1-Tages-Spanne:
Value
$3.03
$3.28
1-Wochen-Bereich:
Value
$2.82
$3.41
52-Wochen-Spanne:
Value
$2.585
$12.80

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name
Firmenname
Tango Therapeutics Inc
Name
Telefon
(857) 320-4900
Name
Adresse
201 BROOKLINE AVENUE, BOSTON
Name
Mitarbeiter
140
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
TNGX's Discussions on Twitter

Vergleichen Sie TNGX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TNGX
Tango Therapeutics Inc
3.03 325.48M 42.51M -116.49M -120.82M -1.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.32 120.86B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
710.00 77.62B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
646.64 39.62B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
276.19 35.50B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.61 28.20B 3.30B -501.07M 1.03B -2.1146

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-17 Eingeleitet Jefferies Buy
2024-04-04 Eingeleitet Cantor Fitzgerald Overweight
2024-02-12 Eingeleitet Piper Sandler Overweight
2023-12-08 Eingeleitet B. Riley Securities Buy
2022-10-20 Hochstufung H.C. Wainwright Neutral → Buy
2021-09-20 Eingeleitet SVB Leerink Outperform
Alle ansehen

Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten

pulisher
02:37 AM

What is Leerink Partnrs' Forecast for TNGX Q3 Earnings? - MarketBeat

02:37 AM
pulisher
Feb 09, 2025

Barbara Weber Sells 9,778 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

Adam Crystal Sells 7,432 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

Tango Therapeutics Inc (NASDAQ: TNGX): Can A Stock Be -1.94% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

One Tango Therapeutics Insider Raised Stake By 400% In Previous Year - Yahoo Finance

Feb 08, 2025
pulisher
Feb 08, 2025

What is Leerink Partnrs’ Estimate for TNGX Q1 Earnings? - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Insider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Sells 4,284 Shares of Stock - MarketBeat

Feb 07, 2025
pulisher
Feb 07, 2025

What is Leerink Partnrs' Estimate for TNGX Q1 Earnings? - MarketBeat

Feb 07, 2025
pulisher
Feb 07, 2025

Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN

Feb 07, 2025
pulisher
Feb 06, 2025

Tango Therapeutics CEO Barbara Weber sells $57,710 in stock By Investing.com - Investing.com Canada

Feb 06, 2025
pulisher
Feb 06, 2025

Tango Therapeutics executive sells shares worth $43,865 By Investing.com - Investing.com South Africa

Feb 06, 2025
pulisher
Feb 06, 2025

Tango Therapeutics general counsel Barry Douglas sells $16,369 in stock - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Is Tango Therapeutics Inc (TNGX) worth investing in despite its overvalued state? - US Post News

Feb 06, 2025
pulisher
Feb 06, 2025

TNGX’s 2023 Market Dance: Up 8.41% – Time to Invest? - The InvestChronicle

Feb 06, 2025
pulisher
Feb 05, 2025

Exclusive BAC Article: Tango Therapeutics; 2nd Half Of 2024 MTAP-Deletion Tumor Data TNG-908/TNG-462, TNG-260 Phase 1/2 Trial Advancement And Catalysts (NASDAQ:TNGX) - Seeking Alpha

Feb 05, 2025
pulisher
Feb 05, 2025

TNGX (Tango Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Tango Therapeutics Inc’s Market Journey: Closing Strong at 3.04, Up 4.47 - The Dwinnex

Feb 05, 2025
pulisher
Feb 01, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $13.14 Average Price Target from Analysts - MarketBeat

Feb 01, 2025
pulisher
Jan 30, 2025

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - The Manila Times

Jan 30, 2025
pulisher
Jan 30, 2025

Precision Cancer Medicine Pioneer Tango Therapeutics Takes Center Stage at Elite Biotech Conference - StockTitan

Jan 30, 2025
pulisher
Jan 29, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Jan 29, 2025
pulisher
Jan 23, 2025

Tango Therapeutics: Chance For A Short Squeeze - Seeking Alpha

Jan 23, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Estimates TNGX FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Forecasts TNGX FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 15, 2025

Tango Therapeutics' Stock Sinks To US$2.62, But Insiders Sold Even Lower - Simply Wall St

Jan 15, 2025
pulisher
Jan 15, 2025

Barclays PLC Has $972,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

Tango Therapeutics Highlights Breakthroughs in Cancer Treatment - TipRanks

Jan 13, 2025
pulisher
Jan 08, 2025

Jane Street Group LLC Has $391,000 Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 08, 2025
pulisher
Jan 04, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Buy" by Analysts - MarketBeat

Jan 04, 2025
pulisher
Jan 03, 2025

Franklin Resources Inc. Has $126,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 03, 2025
pulisher
Jan 01, 2025

Geode Capital Management LLC Has $10.54 Million Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jan 01, 2025
pulisher
Dec 31, 2024

Barclays PLC Raises Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 31, 2024
pulisher
Dec 24, 2024

State Street Corp Purchases 489,949 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 24, 2024
pulisher
Dec 24, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Purchased by State Street Corp - MarketBeat

Dec 24, 2024
pulisher
Dec 21, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $580,000 Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 21, 2024
pulisher
Dec 17, 2024

The Manufacturers Life Insurance Company Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Dec 17, 2024
pulisher
Dec 14, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com India

Dec 14, 2024
pulisher
Dec 14, 2024

Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa

Dec 14, 2024
pulisher
Dec 13, 2024

TNGX Stock Hits 52-Week Low at $2.7 Amid Market Challenges - Investing.com UK

Dec 13, 2024
pulisher
Dec 10, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Dec 10, 2024
pulisher
Dec 07, 2024

Cantor Fitzgerald Reaffirms Overweight Rating for Tango Therapeutics (NASDAQ:TNGX) - Defense World

Dec 07, 2024
pulisher
Dec 05, 2024

Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register

Dec 05, 2024
pulisher
Dec 05, 2024

Unveiling 5 Analyst Insights On Tango Therapeutics - Benzinga

Dec 05, 2024
pulisher
Dec 05, 2024

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth? - Simply Wall St

Dec 05, 2024
pulisher
Dec 03, 2024

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Dec 03, 2024
pulisher
Nov 29, 2024

Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 21.7% - MarketBeat

Nov 29, 2024

Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$79.95
price down icon 1.03%
$20.11
price down icon 2.71%
$347.71
price down icon 1.71%
$4.69
price down icon 6.94%
biotechnology ONC
$223.50
price down icon 2.35%
$117.61
price down icon 1.94%
Kapitalisierung:     |  Volumen (24h):